Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing.
Autologous stem cell transplantation
Mantle cell lymphoma
Measurable residual disease
Minimal residual disease
Relapse
Journal
Leukemia research reports
ISSN: 2213-0489
Titre abrégé: Leuk Res Rep
Pays: England
ID NLM: 101608906
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
01
2022
revised:
01
07
2022
accepted:
07
08
2022
entrez:
30
8
2022
pubmed:
31
8
2022
medline:
31
8
2022
Statut:
epublish
Résumé
High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) has become a treatment option for fit patients with mantle cell lymphoma (MCL). However, these patients often relapse within few years, potentially caused by contaminating lymphoma cells within the reinfused stem cell product (SCP). Studies have shown that measurable residual disease, also termed minimal residual disease (MRD), following ASCT predicts shorter survival. Using next-generation sequencing, we explore whether the diagnostic MCL clonotype is present within the infused SCP. MRD was detected in 4/17 of the SCPs, ranging 4-568 clonal cells/100,000 cells. With a median survival of 17 months, 3/4 of patients with MRD+ graft succumbed from MCL relapse versus 2/13 in the MRD- fraction. Patients receiving MRD+ grafts had increased risk of mortality, and thus screening of SCPs may be important for clinical decision-making.
Identifiants
pubmed: 36039182
doi: 10.1016/j.lrr.2022.100341
pii: S2213-0489(22)00053-X
pmc: PMC9418493
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100341Informations de copyright
© 2022 The Authors. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
The authors have nothing to disclose.
Références
Blood. 2020 Feb 27;135(9):680-688
pubmed: 31932839
Leukemia. 2019 Sep;33(9):2227-2240
pubmed: 31197258
Leukemia. 2003 Dec;17(12):2257-317
pubmed: 14671650
Curr Opin Hematol. 1997 Nov;4(6):423-8
pubmed: 9359000
Blood. 2000 Aug 1;96(3):864-9
pubmed: 10910898
Leukemia. 2014 Jun;28(6):1299-307
pubmed: 24342950
Blood. 2006 Mar 15;107(6):2271-8
pubmed: 16332971
Ann Oncol. 2017 Oct 01;28(10):2503-2510
pubmed: 28945825
Crit Rev Oncol Hematol. 2002 Feb;41(2):241-50
pubmed: 11856599
Exp Hematol. 2021 Jun;98:14-24
pubmed: 33823225
Haematologica. 2017 Jul;102(7):1133-1136
pubmed: 28655809
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):230-237.e12
pubmed: 33558202
Blood. 2008 Oct 1;112(7):2687-93
pubmed: 18625886
Cancers (Basel). 2021 May 23;13(11):
pubmed: 34071000
Blood. 1997 Jan 15;89(2):724-31
pubmed: 9002976
Br J Haematol. 2018 Jun;181(5):703-706
pubmed: 28444739
J Cancer. 2021 Jan 1;12(2):553-561
pubmed: 33391451